Orchid Pharma registers turnover of Rs 211 crore in Q2 FY16, EBITDA of Rs 43 crore.
Chennai, India | November 9, 2015
Financialhighlights for Quarter ended September 30, 2015 (Q2 FY16) – Standalone
Revenue of Rs 210.8 crore (US$ 31.8million) in the quarter ended September 30, 2015 (Q1 FY16) as compared to Rs 174.9crore (US$ 26.4 million) registered during the quarter ended September 30, 2014(Q4 FY15).
EBITDA of Rs 43.4 crore (US$ 6.5 million)in the quarter ended September 30, 2015 as compared to Rs -11.4 crore (US$ -1.7million) in the quarter ended September 30, 2014.
At the net level, the company registered aloss of Rs 68.9 crore (US$ 10.4 million) during the quarter ended September 30,2015 as compared to a profit of Rs 271.9 crore (US$ 41.0 million) for the correspondingquarter ended September 30, 2014, which included an extra-ordinary income ofRs.318.8 Crore ( US$ 48.1 million)
* 1 US$ = Rs 66.30
From the Managing Director
“The businessis gradually gaining traction and we hope to come back with a stronger revenuepattern going forward, through the various growth measures that we areundertaking”, said Mr K Raghavendra Rao, Managing Director, Orchid Pharma Ltd.
OrchidPharma Ltd (formerly known as Orchid Chemicals & Pharmaceuticals Ltd.) was bestowedwith the Export Excellence award for the year 2012-13 and 2013-14 for thelargest exporter under the category of EOUs operating under the MEPZ SpecialEconomic Zone, Government of India, Chennai.
OrchidPharma Ltd. is a leading pharmaceutical companyheadquartered in Chennai, India involved in the development; manufacture andmarketing of diverse bulk actives, formulations and nutraceuticals. Withexports spanning more than 75 countries, Orchid is the largestmanufacturer-exporter of cephalosporin bulk actives in India and is rankedamongst the Top 5-cephalosporin producers in the world. Orchid’s world-class manufacturing infrastructure including USFDA and UKMHRA approved API and dosage form facilities located at Chennai. Orchid hasdedicated state-of-the-art GLP compliant R&D centres for API research, drugdiscovery and pharmaceutical research at Chennai. Orchid has ISO 14001 andOHSAS 18001 certifications. Orchid is listed on the National Stock Exchange(NSE) and Bombay Stock Exchange (BSE) in India.
Additional information is available at the company’swebsite at www.orchidpharma.com
This release may include forward-looking statementsand information that involve risks, uncertainties and assumptions.Forward-looking statements are all statements that concern plans, objectives,goals, strategies, future events or performance and underlying assumptions andother statements that are other than statements of historical fact, including,but not limited to, those that are identified by the use of words such as“anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,”“predicts,” “projects” and similar expressions. Risks and uncertainties thatcould affect us include, without limitation:
General economic and business conditions in the markets we operate in;
The ability to successfully implement our strategies, our research anddevelopment efforts, growth and expansion plans and technological changes;
Changes in the value of the Rupee and other currency changes;
Changes in the Indian and international interest rates;
Changes in laws and regulations that apply to our customers, suppliers,and the pharmaceutical industry;
Increasing competition in and the conditions of our customers, suppliersand the pharmaceutical industry
Shouldone or more of such risks and uncertainties materialize, or should anyunderlying assumption prove incorrect, actual outcomes may vary materially fromthose indicated in the applicable forward-looking statements. Anyforward-looking statement or information contained in this presentation speaksonly as of the date of the statement. We are not required to update any suchstatement or information to either reflect events or circumstances that occurafter the date the statement or information is made or to account forunanticipated events.